Subscribe to our Newsletters !!
Fermentation is a natural method which is applied
With the MAGIO series, Julabo is expanding its pro
The human metapneumovirus, more simply referred to
We are truly honored to share that HiMedia Laborat
Alembic Pharmaceuticals Limited (Alembic) announce
'Simplicity' seems to be the perfect word to descr
Dear Readers, Welcome to the latest issue of Mi
Central Islip, New York, USA & Mumbai, India; July 22, 2019: – InvaGen Pharmaceuticals, Inc. (“InvaGen”), a wholly-owned subsidiary of the leading global pharmaceutical company Cipla Limited (BSE: 500087; NSE: CIPLA EQ; hereafter referred to as "Cipla") announced the receipt of final approval for its Abbreviated New Drug Application (ANDA) for Pregabalin Capsules, 25mg, 50mg, 75mg, 100mg, 150mg, 200mg, 225mg and 300mg from the United States Food and Drug Administration (US FDA).
InvaGen’s Pregabalin Capsules, 25mg, 50mg, 75mg, 100mg, 150mg, 200mg, 225mg and 300mg is AB-rated generic therapeutic equivalent version of Pfizer’s Lyrica®. Pregabalin capsules are indicated for:
• Management of neuropathic pain associated with diabetic peripheral neuropathy
• Management of postherpetic neuralgia
• Adjunctive therapy for the treatment of partial onset seizures in patients 17 years of age and older
• Management of fibromyalgia
rn• Management of neuropathic pain associated with spinal cord injuryrn
According to IQVIA (IMS Health), Lyrica® had US sales of approximately $5.4Billion for the 12month period ending March 2019. The product is available for shipping immediately.